While spending on oncology drugs in the U.S. is anticipated to reach $125 billion by 2027, overall drug savings of...
Momentum is building for more state legislators to have health insurance companies pay for biomarker testing for patients with cancer....
The idea of value-based care has been around since the late 1960s, when the American Academy of Pediatrics first introduced...
Culver City, California and San Diego – June 19, 2018 – NantHealth (NASDAQ: NH), a next-generation healthcare company, will exhibit and present...
Los Angeles, CA – June 15, 2015 – NantOmics, a leading next generation molecular diagnostic company and wholly owned subsidiary of...
NantHealth and UHS to jointly deliver genomic and transcriptomic sequencing platform and analytics capabilities, incorporating NantHealth’s intelligent clinical operating system...